Previous close | 4.2000 |
Open | 4.0800 |
Bid | 3.9600 x N/A |
Ask | 4.0800 x N/A |
Day's range | 4.0800 - 4.0800 |
52-week range | 3.9400 - 12.2000 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
(Reuters) -A Washington-based global trade association representing biotechnology companies is taking steps to "separate" from Chinese member Wuxi AppTec , according to a letter from its new CEO on Wednesday. The Biotechnology Innovation Organization (BIO) also said it would support proposed legislation that restricts U.S. business with WuXi AppTec and other biotech companies of concern, changing its position from last month. WuXi AppTec, in a letter to BIO dated Tuesday that it provided to Reuters, said it was ending its membership in the organization.
HONG KONG/BEIJING (Reuters) -Hong Kong-listed shares of China's WuXi AppTec jumped as much as 9.8% on Monday after it said it has no links with any governments or their military organisations, and it should not be listed as a "biotechnology company of concern" in a draft U.S. bill. The drug research and development group said in a filing to the Shanghai Stock Exchange on Sunday that it has no human genomics business and does not collect human genome data in any of its existing businesses. A U.S. congressional committee focused on China has introduced a bill that would restrict federally funded medical providers from contracting WuXi AppTec and other Chinese biotech companies, citing WuXi AppTec's alleged military ties as part of the reason.